- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Large Cap High Growth Potential
Hong Kong Pharmaceuticals & Biotech Large Cap High Growth Potential
Results
6
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
6 companies
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$122.1b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$523.50
7D
20.2%
1Y
48.6%
Akeso
Market Cap: HK$93.9b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$101.90
7D
11.2%
1Y
-9.8%
WuXi XDC Cayman
Market Cap: HK$80.0b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$63.45
7D
8.8%
1Y
45.9%
Innovent Biologics
Market Cap: HK$157.3b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.
1801
HK$90.50
7D
13.1%
1Y
9.6%
Sino Biopharmaceutical
Market Cap: HK$90.0b
An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
1177
HK$5.05
7D
12.5%
1Y
-8.2%
WuXi Biologics (Cayman)
Market Cap: HK$155.4b
An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil.
2269
HK$37.80
7D
7.1%
1Y
50.9%